Neoadjuvant Radiotherapy Before Surgery for Rectal Cancer, Surgical and Oncological Outcome Analysis, Retrospective Case Control Study in a Single Institute.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- General Surgery
- Sponsor
- Taichung Veterans General Hospital
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Recurrence rate
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
Pre-operative radiotherapy for clinical stage 3 rectal cancer outcome analysis, retrospective case-control study.
Detailed Description
For clinical T3 rectal cancer, neo-adjuvant radiotherapy was proved to reduce local recurrent rate in the clinical trials. In this study, we analysis surgical and oncological outcomes of neo-adjuvant radiotherapy for stage 3 rectal cancer in the real world in a single institute and do further subgroups analysis as references for treatment plans.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Rectal cancer, clinical stage T3 or higher, with no distant metastasis.
- •Age \> =20 years, ASA class I-III.
- •Underwent surgery.
- •Complete medical records.
Exclusion Criteria
- •Non-rectal cancer.
- •Clinical stage T1-T
- •Stage IV with distant metastasis.
- •Age \< 20 years, ASA class IV-V.
- •Incomplete medical records.
- •HIV-positive patients (Human Immunodeficiency Virus).
- •Patients who completed treatment after October 1, 2024.
Outcomes
Primary Outcomes
Recurrence rate
Time Frame: 5-year postoperative period
The disease recurrence rate refers to the likelihood of a disease reappearing after initial treatment, encompassing both local recurrence and distant metastasis. Local recurrence is defined by medical standards as the reappearance of a tumor at the original site or nearby lymph nodes, typically confirmed through imaging or pathological examination and commonly occurring within 1-3 years post-surgery. Distant metastasis, on the other hand, is identified when tumor cells spread to distant organs, such as the liver, lungs, or bones, and is confirmed through imaging modalities (e.g., CT, MRI, or PET scans) or biopsy. The incidence of distant metastasis is closely related to tumor staging, such as the TNM classification.
survival rate
Time Frame: 5-year postoperative period
This refers to the percentage of patients who are alive at a certain point in time after treatment, often 5 years, from diagnosis or start of treatment. The 5-year survival rate is commonly used in cancer research.
Secondary Outcomes
- Complication rate(30 days after surgery)
- Complications of radiation and chemotherapy(30 days after radiation and chemotherapy)